Department of Neurology, The First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou, China.
Department of Interventional Neuroradiology, Beijing Neurosurgical Institute and Beijing Tiantan Hospital, Capital Medical University, NansanhuanXilu 119, Fengtai District, Beijing, 100070, China.
BMC Neurol. 2021 May 15;21(1):198. doi: 10.1186/s12883-021-02180-1.
The Low-profile Visualized Intraluminal Support (LVIS) device is a self-expanding, nitinol, single-braid, closed-cell device that was recently developed for endovascular embolization of intracranial aneurysms. However, current knowledge regarding the use of LVIS devices to treat vertebral and basilar artery aneurysms is limited. We aimed to evaluate the feasibility, efficacy, and safety of the LVIS device for treating vertebral and basilar artery aneurysms.
Between January 2015 and December 2017, patients with vertebral and basilar artery aneurysms treated using LVIS stents were enrolled in this study. We analyzed patients' demographic, clinical and aneurysmal characteristics, procedural details, complications, and angiographic and clinical follow-up results.
We identified 63 patients with 64 vertebral and basilar artery aneurysms who underwent treatment with (n = 59) or without (n = 5) LVIS stenting, including 10 patients with ruptured aneurysms. Forty-one aneurysms were located at the vertebral artery, and 23 at the basilar artery. Intraprocedural-related complications developed in three (4.8%) patients, while none of these patients developed morbidities or died during follow-up. Three patients developed post-procedural complications (4.8%). Two patients experienced ischemic events immediately post-procedure. A minor permanent morbidity developed in one of the two patients (1.6%). The mortality rate was 1.6%, for that the patient died of brainstem hemorrhage after 1 month of follow-up. At a mean follow-up of 12.5 months, 39/43 (90.7%) patients had stable or improved aneurysms, and four (9.3%) had recanalized.
LVIS device of vertebral and basilar artery aneurysms may be an acceptable safety profile and may represent a reasonable treatment option in the short-term. Long-term and larger cohort studies are necessary to validate our results.
低轮廓可视化腔内支撑(LVIS)装置是一种自膨式、镍钛诺、单编织、闭孔的装置,最近被开发用于颅内动脉瘤的血管内栓塞。然而,目前对于使用 LVIS 装置治疗椎动脉和基底动脉动脉瘤的知识有限。我们旨在评估 LVIS 装置治疗椎动脉和基底动脉动脉瘤的可行性、疗效和安全性。
2015 年 1 月至 2017 年 12 月,我们对使用 LVIS 支架治疗的椎动脉和基底动脉动脉瘤患者进行了这项研究。我们分析了患者的人口统计学、临床和动脉瘤特征、手术细节、并发症以及血管造影和临床随访结果。
我们确定了 63 例接受 LVIS 支架治疗(n=59)或未治疗(n=5)的椎动脉和基底动脉动脉瘤患者,其中 10 例为破裂性动脉瘤。41 个动脉瘤位于椎动脉,23 个位于基底动脉。术中相关并发症发生在 3 例(4.8%)患者中,而这些患者在随访期间均无发生严重并发症或死亡。术后发生 3 例并发症(4.8%)。2 例患者术后即刻发生缺血事件。1 例患者发生轻微永久性并发症(1.6%)。死亡率为 1.6%,该患者在随访 1 个月后因脑干出血死亡。在平均 12.5 个月的随访中,39/43(90.7%)患者的动脉瘤稳定或改善,4 例(9.3%)患者的动脉瘤再通。
LVIS 装置治疗椎动脉和基底动脉动脉瘤可能具有可接受的安全性,并可能在短期内成为一种合理的治疗选择。需要进行长期和更大队列的研究来验证我们的结果。